U.S. Patent Number
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Animals were immunized with purified bacterially expressed fusion proteins containing BRCA1 amino acids 1360 to 1555. Spleen cells were fused with the mouse myeloma cell line P3.653. Monoclonal antibodies BR1H-788.6 (ATCC PTA-4301), BR1H-945.2 (ATCC PTA-4303) and BR1H-826.5 (ATCC PTA-4302) are against a portion of a BRCA1 polypeptide between the N-terminal and C-terminal regions of the BRCA1 polypeptide (amino acids 1360 to 1555). Monoclonal antibodies BR1N.129.5 (ATCC PTA-4304) and BR1N-411.4 (ATCC PTA-4305) are against the N-terminal region of a BRCA1 polypeptide (amino acids 1 to 304). Monoclonal antibodies BR1S-218.1 (ATCC PTA-4307), BR1S-060.2 (ATCC PTA-4306), BR1S-384.5 (ATCC PTA-4308), and BR1S-425.1 (ATCC PTA-4309) are against the C-terminal region of a full-length BRCA1 polypeptide (amino acids 1840-1862). These antibodies can be used to detect BRCA1 mutations.
Shipped frozen
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished.
Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation

Knott CL, Kuus-Reichel K. Methods of detecting BRCA1 mutations. U.S. Patent 6,514,713 dated Feb 4 2003